Cabazitaxel
|
|
|
- CAS-Nr.
- 183133-96-2
- Englisch Name:
- Cabazitaxel
- Synonyma:
- Jevtana;Cabazitaxel Injection;CS-877;TXD-258;XRP 6258;Takabasai;Kabatasai;Cabazitaxe;RPR-116258A;Cabazitaxel
- CBNumber:
- CB42517227
- Summenformel:
- C45H57NO14
- Molgewicht:
- 835.93
- MOL-Datei:
- 183133-96-2.mol
|
Cabazitaxel Eigenschaften
- Schmelzpunkt:
- 180 °C
- Siedepunkt:
- 870.7±65.0 °C(Predicted)
- Dichte
- 1.31
- storage temp.
- Inert atmosphere,Store in freezer, under -20°C
- Löslichkeit
- Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly)
- Aggregatzustand
- White solid.
- pka
- 11.20±0.46(Predicted)
- Farbe
- White to Off-White
Sicherheit
- Risiko- und Sicherheitserklärung
- Gefahreninformationscode (GHS)
| S-Sätze: |
24/25 |
|
|
| HS Code |
29329990 |
|
|
| Bildanzeige (GHS) |
 
|
| Alarmwort |
Warnung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H302 |
Gesundheitsschädlich bei Verschlucken. |
Akute Toxizität oral |
Kategorie 4 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P270, P301+P312, P330, P501 |
| H315 |
Verursacht Hautreizungen. |
Hautreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P302+P352, P321,P332+P313, P362 |
| H341 |
Kann vermutlich genetische Defekte verursachen. |
Keimzellmutagenität |
Kategorie 2 |
Warnung |
|
P201,P202, P281, P308+P313, P405,P501 |
| H373 |
Kann die Organe schädigen bei längerer oder wiederholter Exposition. |
Spezifische Zielorgan-Toxizität (wiederholte Exposition) |
Kategorie 2 |
Warnung |
|
P260, P314, P501 |
|
| Sicherheit |
| P202 |
Vor Gebrauch alle Sicherheitshinweise lesen und verstehen. |
| P260 |
Dampf/Aerosol/Nebel nicht einatmen. |
| P264 |
Nach Gebrauch gründlich waschen. |
| P264 |
Nach Gebrauch gründlich waschen. |
| P301+P312 |
BEI VERSCHLUCKEN: Bei Unwohlsein GIFTINFORMATIONSZENTRUM/Arzt/... (geeignete Stelle für medizinische Notfallversorgung vom Hersteller/Lieferanten anzugeben) anrufen. |
| P302+P352 |
BEI BERÜHRUNG MIT DER HAUT: Mit viel Wasser/... (Hersteller kann, falls zweckmäßig, ein Reinigungsmittel angeben oder, wenn Wasser eindeutig ungeeignet ist, ein alternatives Mittel empfehlen) waschen. |
| P308+P313 |
BEI Exposition oder falls betroffen: Ärztlichen Rat einholen/ärztliche Hilfe hinzuziehen. |
|
Cabazitaxel Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
In June 2010, the U.S. FDA approved cabazitaxel (also referred to as
XRP6258 and RPR 116258A) in combination with the steroid prednisone
for the treatment of metastatic Castration-Resistant Prostate Cancer
(mCRPC) for patients who were previously treated with a docetaxelcontaining
regimen for late-stage disease.
Cabazitaxel is a semisynthetic analog of the
natural product taxol, which is isolated from the bark of the yew tree.
Cabazitaxel is a microtubule inhibitor that binds to the taxol-binding site of
tubulin. Similar to other tubulin inhibitors of the taxol class, cabazitaxel
inhibits microtubule disassembly resulting in mitotic blockade and cell
death. Docetaxel, also a semisynthetic taxol analog, was approved by the
FDA for the treatment of mCRPC in 2004. However, docetaxel is a substrate
for P-gp, which is thought to contribute to the constitutive and acquired
resistance of cancer cells to taxanes. Cabazitaxel has poor affinity for P-gp
and showed antitumor activity in preclinical in vitro studies and in vivo
tumor models that overexpress this protein. Cabazitaxel is synthesized on
a commercial scale from 10-deacetylbaccatin .
Chemische Eigenschaften
White solid
Verwenden
Cabazitaxel (Jevtana, XRP6258) is a semi-synthetic derivative of a natural taxoid.
Definition
ChEBI: A tetracyclic diterpenoid that is 10-deacetylbaccatin III having O-methyl groups attached at positions 7 and 10 as well as an O-(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hy
roxy-3-phenylpropanoyl group attached at position 13. Acts as a microtubule inhibitor, binds tubulin and promotes microtubule assembly and simultaneously inhibits disassembly.
Clinical Use
Cabazitaxel was developed by Sanofi-Aventis as an intravenous injectable drug for the treatment of
hormone-refractory metastatic prostate cancer. As a microtubule inhibitor, cabazitaxel differs from docetaxel because it exhibits a much weaker affinity for P-glycoprotein (P-gp), an adenosine
triphosphate (ATP)-dependent drug efflux pump. Cancer cells that express P-gp become resistant
to taxanes, and the effectiveness of docetaxel can be limited by its high substrate affinity for P-gp.
Clinical studies confirmed that cabazitaxel retains activity in docetaxel-resistant tumors. Common
adverse events with cabazitaxel include diarrhea and neutropenia. Cabazitaxel in combination with
prednisone is an important new treatment option for men with docetaxel-refractory metastatic CRPC
(castration-resistant prostate cancer).
Cabazitaxel Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Benzenepropanoic acid, β-[[(1,1-dimethylethoxy)carbonyl]amino]-α-(1-ethoxyethoxy)-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4,6-dimethoxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)-
Benzenepropanoic acid, β-[[(1,1-dimethylethoxy)carbonyl]amino]-α-[(tetrahydro-2H-pyran-2-yl)oxy]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4,6-dimethoxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)-
1380584-07-5
N',O'-(4-Methoxybenzylidene)cabazitaxel
Cabazitaxel N-1
Downstream Produkte
Cabazitaxel Anbieter Lieferant Produzent Hersteller Vertrieb Händler.
Global( 460)Lieferanten
- (2AR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-acetoxy-9-(((2R,3S)-3-((tert-butoxycarbonyl)amino)-2-
- TXD-258
- (αR,βS)-β-[[(1,1-DiMethylethoxy)carbonyl]aMino]-α-hydroxybenzenepropanoic Acid (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(Acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4,6-diMethoxy-4a,8,13,13-tetraMethyl-5-oxo-7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester
- XRP 6258
- Cabazitaxel
- β-[[(1,1-DiMethylethoxy)carbonyl]aMino]-α-hydroxybenzenepropanoic Acid [2aR-[2aα,4β,4aβ,6β,9α(αR*,βS*),11α,12α,12aα,12bα]]-12b-(Acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4,6-diMethoxy-4a,8,13,13-tetraMethyl
- 7β, 10β-DiMethoxydocetaxel
- Cabazitaxel(XRP-6258)
- 7beta, 10beta-DiMethoxydocetaxel
- RPR-116258A
- taxoid XRP6258
- [2aR[2aalpha,4beta,4abeta,6beta,9alpha(2R,3S),11beta,12alpha,12aalpha,12balpha]]-12b-Acetoxy-9-[3-(tert-butoxycarbonylaMino)-2-hydroxy-3-phenylpropionyloxy]-12-(benzoyloxy)-11-hydroxy-4,6-diMethoxy-4a,8,13,13-tetraMethyl-2a,3,4,4a,5,6,9,10,11,12,12a,12b-d
- (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-acetoxy-9-(((2R,3S)-3-((tert-butoxycarbonyl)aMino)-2-hydroxy-3-phenylpropanoyl)oxy)-11-hydroxy-4,6-diMethoxy-4a,8,13,13-tetraMethyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1H-7,11-Methanocyclodeca[3,4]be
- Benzenepropanoic acid, β-[[(1,1-dimethylethoxy)carbonyl]amino]-α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4,6-dimethoxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)-
- Cabazitaxel, >=98%
- XRP6258;RPR-116258A;TAXOID XRP6258;TXD 258
- CS-877
- Cabazitaxel 183133-96-2
- Benzenepropanoic acid, β-[[(1,1-dimethylethoxy)carbonyl]amino]-α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4,6-dimethoxy-
- Cabazitaxel (This product is only available in Japan.)
- [2aR[2aalpha,4beta,4abeta,6beta,9alpha(2R,3S),11beta,12alpha,12aalpha,12balpha]]-12b-Acetoxy-9-[3-(tert-butoxycarbonylamino)-2-hydroxy-3-phenylpropionyloxy]-12-(benzoyloxy)-11-hydroxy-4,6-dimethoxy-4a
- Cabazitaxelum
- (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-Acetoxy-9-((3-((tert-butoxycarbonyl)amino)-2-hydroxy-3-phenylpropanoyl)oxy)-11-hydroxy-4,6-dimethoxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxet-12-yl benzoate
- Cabazitaxel USP/EP/BP
- 7β,10β-Dimethoxydocetaxel
- [2aR[2aalpha,4beta,4abeta,6beta,9alpha(2R,3S),11beta,12alpha...
- (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-Acetoxy-9-((3-((tert-butoxycarbonyl)amino)-2-hydroxy-3-phenylpropanoyl)oxy)-11-hydroxy-4,6-dimethoxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-
- CabazitaxelQ: What is
Cabazitaxel Q: What is the CAS Number of
Cabazitaxel Q: What is the storage condition of
Cabazitaxel Q: What are the applications of
Cabazitaxel
- Jevtana
- Cabazitaxel Injection
- Takabasai
- Benzenepropanoic acid, β-[[(1,1-dimethylethoxy)carbonyl]amino]-α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4,6-dimethoxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester,...
- Kabatasai
- Cabazitaxe
- carbazitaxel
- 183133-96-2
- C45H57NO14
- XRP-6258
- Final material
- Plant extracts
- Herb extract
- Aromatics
- Chiral Reagents
- Inhibitors
- Intermediates & Fine Chemicals
- Pharmaceuticals
- Pharmaceutical intermediate
- API
- APIs
